Grant: Canada Postdoctoral Research Award (CPRA) program
University of Calgary
$140,000.00
Building the First Made-in-Canada Base Editing Pipeline for Inborn Errors of Immunity: Proof-of-Concept in ADA-SCID Q3X
FY 2025-26
Summary
Inborn errors of immunity are inherited diseases caused by mutations, which can be thought of as typos, in DNA that weaken the immune system and lead to serious infections. One of the most severe and relatively common in Canada is adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID). The current best treatment is a bone-marrow transplant from a closely matched donor, but many patients don't have a match, the procedure is costly, and it can cause life-threatening complications from using someone else's cells.
My research aims to fix the DNA mutation directly in a patient's own blood stem cells. I use base editing, an advanced form of the Nobel prize-winning CRISPR genome editing technology, which works like a molecular spellchecker to change a single wrong DNA letter to the correct one. I will test two paths that could reach patients: ex vivo (edit cells outside the body, then reinfuse) and in vivo (deliver the editor directly into the body so it edits the cells in place). I will use ADA-SCID as a proof of concept to establish base editing for the correction of mutations causing inborn errors of immunity.
In the ex vivo approach, I will edit patient-derived stem cells in the lab and test them in cell lines and mice to see if the corrected cells make healthy T cells. In the in vivo approach, I will deliver the editor to stem cells using lipid nanoparticles (the same tiny carriers used in mRNA vaccines) injected into the bloodstream of mouse models.
This important pre-clinical research will create a practical path in Canada for clinical trials for gene correction of ADA-SCID and at least 57 additional immune-gene mutations. In the future, the same pipeline could be adapted to other single-letter genetic diseases such as Beta thalassemia, phenylketonuria, Duchenne muscular dystrophy, and certain familial cancers.
Department
Program
Canada Postdoctoral Research Award (CPRA) program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
536991
Name
Mashayekhi Fatemeh
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Building the First Made-in-Canada Base Editing Pipeline for Inborn Errors of Immunity: Proof-of-Concept in ADA-SCID Q3X
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Adenosine Deaminase; Base Editing; Crispr; Genome Editing; Inborn Errors Of Immunity; Lipid Nanoparticles (Lnp)
Abstract
Inborn errors of immunity are inherited diseases caused by mutations, which can be thought of as typos, in DNA that weaken the immune system and lead to serious infections. One of the most severe and relatively common in Canada is adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID). The current best treatment is a bone-marrow transplant from a closely matched donor, but many patients don't have a match, the procedure is costly, and it can cause life-threatening complications from using someone else's cells.
My research aims to fix the DNA mutation directly in a patient's own blood stem cells. I use base editing, an advanced form of the Nobel prize-winning CRISPR genome editing technology, which works like a molecular spellchecker to change a single wrong DNA letter to the correct one. I will test two paths that could reach patients: ex vivo (edit cells outside the body, then reinfuse) and in vivo (deliver the editor directly into the body so it edits the cells in place). I will use ADA-SCID as a proof of concept to establish base editing for the correction of mutations causing inborn errors of immunity.
In the ex vivo approach, I will edit patient-derived stem cells in the lab and test them in cell lines and mice to see if the corrected cells make healthy T cells. In the in vivo approach, I will deliver the editor to stem cells using lipid nanoparticles (the same tiny carriers used in mRNA vaccines) injected into the bloodstream of mouse models.
This important pre-clinical research will create a practical path in Canada for clinical trials for gene correction of ADA-SCID and at least 57 additional immune-gene mutations. In the future, the same pipeline could be adapted to other single-letter genetic diseases such as Beta thalassemia, phenylketonuria, Duchenne muscular dystrophy, and certain familial cancers.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Mashayekhi, Fatemeh
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~